Perioperative Albumin Among Adults Undergoing Thoracic Surgery in the United States: Utilization, Associations With Clinical Outcomes, and Contribution to Hospital Costs

Abstract

Objectives: To estimate the use of albumin among adults undergoing thoracic surgery in the United States, compare baseline characteristics, clinical and cost outcomes of recipients versus non-recipients, and determine albumin's contribution to total hospital costs. Design: Retrospective cohort study. Setting: Nationwide sample of US hospitals. Participants: Adults undergoing open and minimally invasive thoracic surgery between 2011 and 2017. Interventions: Albumin on the day of surgery (identified using itemized hospital billing logs). Measurements and Main Results: Albumin was used in 170 of 342 US hospitals, among 13% and 7% of 14672 and 22532 patients who respectively underwent open and minimally invasive thoracic surgery (median volume 500cc). Baseline comorbidities and organ supportive treatments were several-fold more prevalent among recipients (particularly vasopressors, mechanical ventilation, red cell transfusions). In standardized mortality ratio propensity score weighted analysis, albumin use was not associated with in-hospital mortality (adjusted RR 1.17 [0.72, 1.92] and 1.51 [0.97, 2.34], with open and minimally procedures), but was associated with morbidity and higher costs, more so with minimally invasive than open surgery. Total costs among recipients were higher by $4,744 [$3,591, $5,897] and $5,088 [$4,075, $6,100] for open and minimally invasive procedures respectively. Albumin accounted for 2.6% of this difference (median $124 [$83-$189] per patient). Conclusions: Albumin use varies widely across hospitals, and 9% of patients receive it (median 500cc). Use was not associated with in-hospital mortality and was associated with more morbidity and cost. The cost of albumin accounted for a trivial portion of hospital costs. Clinical trials must examine effects of albumin on complications and costs after thoracic surgery.